help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lalou, C.
Right arrow Articles by Binoux, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lalou, C.
Right arrow Articles by Binoux, M.

Endocrinology, Vol 135, 2318-2326, Copyright © 1994 by Endocrine Society


ARTICLES

Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells

C Lalou, C Silve, R Rosato, B Segovia and M Binoux
Institut National de la Sante et de la Recherche Medicale, Unite de Recherches sur la Regulation de la Croissance (U-142), Hopital Saint Antonie, Paris, France.

Limited proteolysis in vivo of insulin-like growth factor-binding protein-3 (IGFBP-3) by as yet unidentified serine proteases plays a key role in controlling the bioavailability of IGFBP-3-associated insulin- like growth factors (IGFs). Both the IGF system and the system of plasminogen activators (PAs) and their inhibitors (PAIs) are involved in bone remodeling, and plasmin has been shown to provoke dissociation of IGFBP-IGF complexes in cultured MG-63 human osteoblasts. The aim of this work was to investigate interactions between IGF-I and the PA/PAI system and their influence on IGFBP-3 production and proteolysis in this cell model. At confluency, MG-63 cells maintained for 3 days in serum-free medium constitutively secreted IGFBP-2 and small amounts of IGFBP-3 and IGFBP-4. As shown by Western ligand and immunoblot analyses of the culture medium and Northern blot analysis of IGFBP-3 messenger RNA, production of these IGFBPs, and of IGFBP-3 in particular, was dose dependently stimulated by the addition of 12.5-100 ng/ml recombinant human (rh) IGF-I. Increasing concentrations of plasminogen (0.05-3.5 micrograms/ml) added during the final 12 h of culture reduced the amounts of IGFBP detectable by Western ligand blotting, especially IGFBP-3. This reduction reflected proteolysis, as shown by immunoblotting, which revealed 30-, 20-, and 16-kilodalton fragments of IGFBP-3. In the presence of 25 ng/ml IGF-I, which stimulated IGFBP-3 production, proteolysis was reduced by approximately half. Incubation of glycosylated [125I]rh-IGFBP-3 as substrate in cell-free conditioned medium gave the same results. Addition of 50 ng/ml rhIGF-I to conditioned medium (to promote IGFBP-3-rhIGF-I complex formation) failed to diminish plasmin-induced proteolysis of IGFBP-3. Urokinase PA activity in the conditioned medium decreased significantly when the cells were cultured with rhIGF-I, indicating a direct action of IGF-I on urokinase PA and/or PAI production. Our results support the notion of a regulation loop whereby IGF-I controls its own bioavailability via its action on both IGFBP-3 production and the PA/PAI system, which regulates IGFBP-3 proteolysis. The proteolytic cleavages of IGFBP-3 caused by plasmin were the same as those caused in vivo by serine protease acting on this IGFBP.


This article has been cited by other articles:


Home page
Endocr. Rev.Home page
A. Giustina, G. Mazziotti, and E. Canalis
Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Endocr. Rev., August 1, 2008; 29(5): 535 - 559.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. R. Clemmons, M. Sleevi, and W. H. Busby Jr.
Recombinant, Nonglycosylated Human Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) Is Degraded Preferentially after Administration to Type II Diabetics, Resulting in Increased Endogenous Glycosylated IGFBP-3
J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6561 - 6568.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Miceli, A. Tropea, F. Minici, M. Orlando, G. Lamanna, M. F. Gangale, B. Panetta, F. Tiberi, S. Vaccari, R. Canipari, et al.
Effects of Insulin-Like Growth Factor I and II on Prostaglandin Synthesis and Plasminogen Activator Activity in Human Umbilical Vein Endothelial Cells
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 372 - 378.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. S. Chang, K. Gong, S. Sun, D. Liu, A. K. El-Naggar, F. R. Khuri, W. K. Hong, and H.-Y. Lee
Clinical Significance of Insulin-like Growth Factor-binding Protein-3 Expression in Stage I Non-Small Cell Lung Cancer
Clin. Cancer Res., December 1, 2002; 8(12): 3796 - 3802.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Fanayan, S. M. Firth, and R. C. Baxter
Signaling through the Smad Pathway by Insulin-like Growth Factor-binding Protein-3 in Breast Cancer Cells. RELATIONSHIP TO TRANSFORMING GROWTH FACTOR-beta 1 SIGNALING
J. Biol. Chem., February 22, 2002; 277(9): 7255 - 7261.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. A. Booth, M. Boes, B. L. Dake, K. L. Knudtson, and R. S. Bar
IGFBP-3 binding to endothelial cells inhibits plasmin and thrombin proteolysis
Am J Physiol Endocrinol Metab, January 1, 2002; 282(1): E52 - E58.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Lassarre, F. Duron, and M. Binoux
Use of the Ligand Immunofunctional Assay for Human Insulin-Like Growth Factor (IGF) Binding Protein-3 (IGFBP-3) to Analyze IGFBP-3 Proteolysis and IGF-I Bioavailability in Healthy Adults, GH-Deficient and Acromegalic Patients, and Diabetics
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1942 - 1952.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
C. LASSARRE and M. BINOUX
Measurement of Intact Insulin-Like Growth Factor-Binding Protein-3 in Human Plasma Using a Ligand Immunofunctional Assay
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1260 - 1266.
[Abstract] [Full Text]


Home page
JNCI J Natl Cancer InstHome page
H. Yu and T. Rohan
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. G. Campbell, S. K. Durham, J. D. Hayes, A. Suwanichkul, and D. R. Powell
Insulin-like Growth Factor-binding Protein-3 Binds Fibrinogen and Fibrin
J. Biol. Chem., October 15, 1999; 274(42): 30215 - 30221.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
V. C. Russo, G. Rekaris, N. L. Baker, L. A. Bach, and G. A. Werther
Basic Fibroblast Growth Factor Induces Proteolysis of Secreted and Cell Membrane-Associated Insulin-Like Growth Factor Binding Protein-2 in Human Neuroblastoma Cells
Endocrinology, July 1, 1999; 140(7): 3082 - 3090.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. A. Booth, M. Boes, B. L. Dake, and R. S. Bar
Isolation and characterization of plasmin-generated bioactive fragments of IGFBP-3
Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E450 - E454.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
J. T. Allen, C. A. Bloor, R. A. Knight, and M. A. Spiteri
Expression of Insulin-like Growth Factor Binding Proteins in Bronchoalveolar Lavage Fluid of Patients with Pulmonary Sarcoidosis
Am. J. Respir. Cell Mol. Biol., August 1, 1998; 19(2): 250 - 258.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
P. G. Campbell, S. K. Durham, A. Suwanichkul, J. D. Hayes, and D. R. Powell
Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3
Am J Physiol Endocrinol Metab, August 1, 1998; 275(2): E321 - E331.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Skjærbæk, A. Kaal, J. Møller, N. Vahl, J. Weeke, H. Ørskov, and A. Flyvbjerg
No Effect of Growth Hormone on Serum Insulin-Like Growth Factor Binding Protein-3 Proteolysis
J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1206 - 1210.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
B. Kubler, S. Cowell, J. Zapf, and T. Braulke
Proteolysis of Insulin-Like Growth Factor Binding Proteins by a Novel 50-Kilodalton Metalloproteinase in Human Pregnancy Serum
Endocrinology, April 1, 1998; 139(4): 1556 - 1563.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. Bang and P. J. Fielder
Human Pregnancy Serum Contains at Least Two Distinct Proteolytic Activities with the Ability To Degrade Insulin-Like Growth Factor Binding Protein-3
Endocrinology, September 1, 1997; 138(9): 3912 - 3917.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Xu, P. Savage, J. L. Burton, J. Sansom, and J. M. P. Holly
Proteolysis of Insulin-Like Growth Factor-Binding Protein-3 by Human Skin Keratinocytes in Culture in Comparison to that in Skin Interstitial Fluid: The Role and Regulation of Components of the Plasmin System
J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1863 - 1868.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
H. Salahifar, R. C. Baxter, and J. L. Martin
Insulin-like Growth Factor Binding Protein (IGFBP)-3 Protease Activity Secreted by MCF-7 Breast Cancer Cells: Inhibition by IGFs Does Not Require IGF-IGFBP Interaction
Endocrinology, April 1, 1997; 138(4): 1683 - 1690.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Menouny, M. Binoux, and S. Babajko
Role of Insulin-Like Growth Factor Binding Protein-2 and Its Limited Proteolysis in Neuroblastoma Cell Proliferation: Modulation by Transforming Growth Factor-{beta} and Retinoic Acid
Endocrinology, February 1, 1997; 138(2): 683 - 690.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. L. Andress and D. L. Andress
Heparin Modulates the Binding of Insulin-like Growth Factor (IGF) Binding Protein-5 to a Membrane Protein in Osteoblastic Cells
J. Biol. Chem., November 24, 1995; 270(47): 28289 - 28296.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society